Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

Brian I. Rini; James Brugarolas; Michael B. Atkins

doi:10.1136/jitc-2022-006361

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

Brian I. Rini, James Brugarolas, Michael B. Atkins

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.

Original language	English (US)
Article number	e006361
Journal	Journal for ImmunoTherapy of Cancer
Volume	11
Issue number	3
DOIs	https://doi.org/10.1136/jitc-2022-006361
State	Published - Mar 10 2023
Externally published	Yes

Keywords

Clinical Trials as Topic
Immunotherapy
Kidney Neoplasms

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1136/jitc-2022-006361

Cite this

@article{40f7fa4f32ff44dd9291491e1e261d90,

title = "Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma",

abstract = "Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.",

keywords = "Clinical Trials as Topic, Immunotherapy, Kidney Neoplasms",

author = "Rini, {Brian I.} and James Brugarolas and Atkins, {Michael B.}",

note = "Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",

year = "2023",

month = mar,

day = "10",

doi = "10.1136/jitc-2022-006361",

language = "English (US)",

volume = "11",

journal = "Journal for ImmunoTherapy of Cancer",

issn = "2051-1426",

publisher = "BioMed Central",

number = "3",

}

TY - JOUR

T1 - Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

AU - Rini, Brian I.

AU - Brugarolas, James

AU - Atkins, Michael B.

N1 - Publisher Copyright: © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2023/3/10

Y1 - 2023/3/10

N2 - Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.

AB - Advanced renal cell carcinoma is a biologically heterogeneous disease with multiple treatment options that largely involve immunotherapy and/or anti-angiogenic therapies. The choice of initial and subsequent therapy depends on both clinical and biological considerations. Here, we describe the application of recent data to clinical practice.

KW - Clinical Trials as Topic

KW - Immunotherapy

KW - Kidney Neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85150004387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150004387&partnerID=8YFLogxK

U2 - 10.1136/jitc-2022-006361

DO - 10.1136/jitc-2022-006361

M3 - Review article

C2 - 36898737

AN - SCOPUS:85150004387

SN - 2051-1426

VL - 11

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

IS - 3

M1 - e006361

ER -

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this